Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
Phase 4 N=64 Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants
Bronchiolitis · Wheezing
Primary: Score Respiratory Distress — 8; 8; 6; 8 units on a scale
N/A N=161 Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis
Bronchiolitis · Hypoxia
Primary: Length of Stay in the Hospital — 38.7; 39.5 hours — p=<0.05
N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
Phase 3 N=72 Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients
Bronchiolitis
Primary: Change in Modified Wood's Clinical Asthma Score (M-WCAS) From Baseline to 240 Minutes — 1.84; .031 units on a scale — p=<0.05
Phase 4 N=80 Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing
Asthma
Primary: Mean Rate of Wheezing Attacks — 3.57; 5.72 wheezing attacks/per patient — p=0.05
N/A N=126 The Natural History of Small Airways Physiology in Diseased and Healthy States
Asthma · COPD · Interstitial Lung Disease
Primary: FEV1 — 3.03; 2.32; 3.18; 2.76 L
N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Phase 4 N=62 Hypertonic Saline for Acute Bronchiolitis
Bronchiolitis, Viral · Saline Solution, Hypertonic
Primary: Respiratory Assessment Change Score (RACS) — -1.5; -4 units on a scale — p=0.01
Phase 3 N=15 The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia
Familial Dysautonomia
Primary: Change From Baseline of Forced Vital Capacity — 5.5; 4.7; 0.9 percentage change from baseline
Phase 4 N=60 Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction
Acute Bronchial Obstruction, Asthma
Primary: Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation — 44; 43.67 Liters/minute
N/A N=1,283 Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
N/A N=32 Heated Humidified Oxygen Compared to Dry Oxygen Therapy in Children With Bronchiolitis
Bronchiolitis · Hypoxemia
Primary: Change in Respiratory Distress Assessment Instrument (RDAI) From Baseline. — 4.69; 2.69; 4.27; 3 units on a scale
N/A N=304 The Bronchiolitis Follow-up Intervention Trial
Bronchiolitis
Primary: Parental Anxiety — 4.2; 3.9 points on a scale
N/A N=21 Airway Inflammation in Congenital Diaphragmatic Hernia Patients
Congenital Diaphragmatic Hernia
Primary: Number of Participants With Elevated Sputum Eosinophils — 0 participants
N/A N=141 Trial of Montelukast for Treatment of Acute Bronchiolitis
Bronchiolitis
Primary: Duration of Cough — 13; 11 days
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
N/A N=228 Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters
Bronchiolitis
Primary: Number of Caregiver-reported Symptom-free Days (SFDs) — 118.01; 112.60 Days — p=0.537
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Phase 2 N=40 Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic Bronchitis · Protein-Losing Enteropathies · Healthy
Primary: Primary Endpoint: Number of Subjects That Develop New, Active Bleeding — 0 Participants
N/A N=227 A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis
Bronchiolitis
Primary: Length of Stay in the Study-LOS--Intention to Treat Analysis — 2.1; 2.1 Days — p=0.73
Phase 2 N=40 Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
RSV Bronchiolitis
Primary: IL-8 Concentrations — 12,795; 14,676 Pg/ml — p=0.6
Phase 4 N=196 Prevention of OM-85 on Bronchiectasis Exacerbation
Bronchiectasis With Acute Exacerbation
Primary: Bronchiectasis Exacerbation — 0.98; 0.75 proportion of acute exacerbations
Phase 2 N=21 The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children
Asthma · Bronchial Hyperresponsiveness
Primary: Adenosine Challenge Test — 18.46; 142.61 mg/ml
N/A N=52 Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis
Acute Bronchiolitis
Primary: Respiratory Assessment Change Score (RACS) — 1.68; 1.70 score on a scale
Phase 2 N=88 Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
Phase 3 N=200 Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II
Respiratory Syncytial Virus, Bronchiolitis
Primary: Number of Participants Who Experienced the Occurrence of a Third Episode of Post-RSV Wheezing (Recurrent Wheeze) — 45; 33 Participants — p=0.08
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
Phase 4 N=10 Aerosolized Beta-Agonist Isomers in Asthma
Asthma
Primary: Change in Maximum Forced Expiratory Volume at One Second (FEV1) — 20; 20; 20; 19 percentage of change